Search results for "adrenal"

showing 10 items of 416 documents

How to manage aspergillosis in non-neutropenic intensive care unit patients.

2014

Invasive aspergillosis has been mainly reported among immunocompromised patients during prolonged periods of neutropenia. Recently, however, non-neutropenic patients in the ICU population have shown an increasing risk profile for aspergillosis. Associations with chronic obstructive pulmonary disease and corticosteroid therapy have been frequently documented in this cohort. Difficulties in achieving a timely diagnosis of aspergillosis in non-neutropenic patients is related to the non-specificity of symptoms and to lower yields with microbiological tests compared to neutropenic patients. Since high mortality rates are typical of invasive aspergillosis in critically ill patients, a high level …

medicine.medical_specialtyPediatricsChronic ObstructiveAntifungal AgentsCritical IllnessPopulationPulmonary diseaseSettore MED/41 - AnestesiologiaReviewNeutropeniaOpportunistic InfectionsAspergillosisCritical Care and Intensive Care MedicineCommunicable DiseasesCommunicable Diseases Emerginglaw.inventionPulmonary DiseaseImmunocompromised HostPulmonary Disease Chronic ObstructiveAspergillosis non-neutropenic ICUlawAdrenal Cortex HormonesRisk FactorsEpidemiologymedicinenon-neutropenicPrevalenceAspergillosisHumansIntensive care medicineeducationEmergingeducation.field_of_studybusiness.industryIncidence (epidemiology)Medicine (all)IncidenceAdrenal Cortex Hormones; Antifungal Agents; Aspergillosis; Communicable Diseases Emerging; Critical Illness; Humans; Incidence; Intensive Care Units; Opportunistic Infections; Prevalence; Prognosis; Pulmonary Disease Chronic Obstructive; Risk Factors; Immunocompromised Host; Critical Care and Intensive Care Medicinemedicine.diseasePrognosisIntensive care unitAdrenal Cortex Hormones; Antifungal Agents; Aspergillosis; Communicable Diseases Emerging; Critical Illness; Humans; Incidence; Intensive Care Units; Opportunistic Infections; Prevalence; Prognosis; Pulmonary Disease Chronic Obstructive; Risk Factors; Immunocompromised HostIntensive Care UnitsCohortICUAdrenal Cortex Hormones; Antifungal Agents; Aspergillosis; Communicable Diseases Emerging; Critical Illness; Humans; Incidence; Intensive Care Units; Opportunistic Infections; Prevalence; Prognosis; Pulmonary Disease Chronic Obstructive; Risk Factors; Immunocompromised Host; Critical Care and Intensive Care Medicine; Medicine (all)businesssepsis aspergillosis icu managementCritical care (London, England)
researchProduct

Pityriasis rosea Gibert triggered by SARS-CoV-2 infection: A case report.

2021

RATIONALE: Pityriasis rosea Gibert is an erythematous-papulosquamous dermatosis that frequently occurs in young adults. The etiopathogenesis of PR is still unknown, but is frequently associated with episodes of upper respiratory tract infections. It is likely that a new viral trigger of pityriasis rosea is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). PATIENT CONCERNS: We present the case of a female patient in whom the diagnosis of pityriasis rosea led to the investigation and diagnosis of the SARS-CoV-2 infection. The patient presented to the Department of Dermatology for a 3 week duration of an extremely pruritic erythematous-squamous lesion, initially on the trunk …

medicine.medical_specialtyPityriasis RoseaContext (language use)Lesion03 medical and health sciencescoronavirus disease 20190302 clinical medicineAdrenal Cortex HormonesmedicineHumans030212 general & internal medicineClinical Case ReportRespiratory tract infectionsbusiness.industrySARS-CoV-24900COVID-19pityriasis rosea GibertGeneral MedicineMiddle Agedmedicine.diseaseDermatologyRashTopical medicationmedicine.anatomical_structure030220 oncology & carcinogenesisPityriasis roseaEtiologyFemalemedicine.symptombusinessRespiratory tractResearch Articlesevere acute respiratory syndrome coronavirus 2Medicine
researchProduct

Herpes simplex virus type 1 and 2 in the adrenal glands: Replication and histopathology

1986

The adrenal glands were shown to be the most severely infected organs in the early phase of HSV-1 infections (up to 10 days p.i.) after i.p. infections in mice. Virus could be isolated from the adrenal glands as early as one hour after infection with pathogenic and apathogenic strains. Infection of the adrenal glands is a result of viremia. The content of HSV-1 (5 strains) was much higher in the adrenals than in spleen and liver. It peaked at 3-4 days p.i. compared to 1-2 days in spleen and liver. Only strain 17 syn+ produced low tissue titres in the adrenal glands. Morphologic alterations by HSV-1 infections commenced with distinct foci 2 days after infection in the zona fasciculata, detec…

medicine.medical_specialtyRatónViremiaSpleenBiologyVirus Replicationmedicine.disease_causeHerpesviridaeVirusMiceVirologyAdrenal GlandsmedicineAnimalsSimplexvirusAntigens ViralAdrenal glandHerpes SimplexGeneral Medicinemedicine.diseaseVirologymedicine.anatomical_structureHerpes simplex virusLiverFemaleHistopathologySpleenArchives of Virology
researchProduct

Accuracy of SCORTEN and ABCD‐10 to predict mortality and the influence of renal function in Stevens–Johnson syndrome/toxic epidermal necrolysis

2020

Epidermal necrolysis (EN) compromises a spectrum of life-threatening dermatoses (Stevens-Johnson Syndrome [SJS], overlap syndrome and toxic epidermal necrolysis [TEN]). Currently, no active therapeutic regimen with unequivocal benefit exists for SJS/TEN. SCORTEN is the widely-used prognostic scale specific for SJS/TEN. Nevertheless, a new prognostic scale, the ABCD-10, has been recently proposed. In this context, acute renal failure (ARF) seems to be an important comorbidity that could influence prognosis in SJS/TEN patients more than it is assumed by these two scales. Our objectives were to compare the accuracy of the SCORTEN and ABCD-10 scales in predicting the mortality in SJS/TEN, and t…

medicine.medical_specialtyRenal functionContext (language use)ComorbidityDermatologyEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicinemedicineHumansRetrospective Studiesbusiness.industryOverlap syndromeStevens johnsonGeneral MedicinePrognosismedicine.diseaseComorbidityToxic epidermal necrolysisstomatognathic diseasesSupportive psychotherapyStevens-Johnson Syndrome030220 oncology & carcinogenesisbusinessmedicine.drugThe Journal of Dermatology
researchProduct

Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: A real-life study

2019

Background:Conventional glucocorticoid treatment has a significant impact on liver in patients with adrenal insufficiency. Dual-release hydrocortisone (DR-HC) provides physiological cortisol exposure, leading to an improvement in anthropometric and metabolic parameters. We aimed to evaluate the effects of 12-month DR-HC treatment on the hepatic steatosis index (HSI), a validated surrogate index of hepatic steatosis, in patients with secondary adrenal insufficiency (SAI).Methods:A total of 45 patients with hypopituitarism, 22 with hypogonadism, hypothyroidism, ACTH, and GH deficiencies, and 23 with hypogonadism, hypothyroidism, and ACTH deficiency, on replacement therapy for all the pituitar…

medicine.medical_specialtySecondary adrenal insufficiencyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismHypopituitarismHepatic steatosilcsh:Diseases of the endocrine glands. Clinical endocrinologyHypopituitarismSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdrenal insufficiencyIn patientHydrocortisoneOriginal Researchlcsh:RC648-665business.industryhepatic steatosismedicine.diseaseInsulin sensitivityEndocrinology030220 oncology & carcinogenesisDual-release hydrocortisoneSteatosisLife studybusinessGlucocorticoidmedicine.drugSecondary adrenal insufficiency
researchProduct

Chirurgie der kindlichen Nebenniere. Operationstaktik, intra- und perioperative Überwachung

1988

Surgical and non-surgical conditions of the adrenal cortex and medulla are presented. Besides general principles of operative treatment (e.g. surgical approach, safe operative technique, bilateral exploration) specific aspects associated with this procedure in childhood are discussed. The perioperative management and pharmacotherapeutical preparation (e.g. hormonal substitution) are emphasized.

medicine.medical_specialtySurgical approachPerioperative managementAdrenal surgeryAdrenal cortexbusiness.industryPerioperativeSurgerymedicine.anatomical_structureAnesthesiaPediatrics Perinatology and Child HealthmedicineSurgerybusinessMedullaEuropean Journal of Pediatric Surgery
researchProduct

Short- and long-term effects of vinblastine on the rat adrenal medulla

1979

The effects of a single high dose (10mg/kg) of vinblastine (vb) sulfate (“Velbe”, Lilly) on the ultrastructure, catecholamine (CA) content and activity of CA-synthesizing enzymes of the rat adrenal medulla were studied for up to 120h after intravenous injection of the drug.

medicine.medical_specialtyTime FactorsHistologyChemical PhenomenaVinblastinePathology and Forensic MedicineInternal medicineSingle high doseEnterochromaffin CellsmedicineAnimalsCells Culturedchemistry.chemical_classificationCell BiologyMolecular medicineRatsVinblastineChemistryEnzymemedicine.anatomical_structureEndocrinologychemistryAdrenal MedullaUltrastructureCatecholamineFemaleAdrenal medullamedicine.drugCell and Tissue Research
researchProduct

Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases

2013

Abstract Background Bisphosphonates (BPs) are currently the chief drugs for the prevention/treatment of osteoporosis; one of their adverse effects is the osteonecrosis of the jaw (BRONJ). The primary endpoints of this multi-center cross-sectional study are: i) an observation of the clinical features of BRONJ in 87 osteoporotic, non-cancer patients; and ii) an evaluation of their demographic variables and comorbidities. Methods 87 BRONJ patients in therapy for osteoporosis with BPs from 8 participating clinical Italian centers were consecutively identified and studied. After BRONJ diagnosis and staging, comorbidities and data relating to local and drug-related risk factors for BRONJ were col…

medicine.medical_specialtyTime FactorsMultivariate analysisHeart DiseasesOsteoporosisSettore MED/50 - Scienze Tecniche Mediche ApplicateAdministration OralMandibleOsteonecrosis jawHospital based studyAdrenal Cortex HormonesRisk FactorsSettore MED/28 - Malattie OdontostomatologicheInternal medicineDiabetes MellitusInternal MedicinemedicineHumansIn patientRisk factorOral bisphopshonateAdverse effectOsteoporosis PostmenopausalAgedRetrospective StudiesAged 80 and overAlendronateBone Density Conservation AgentsDiphosphonatesbusiness.industryLiver DiseasesIncidence (epidemiology)Age FactorsMiddle Agedmedicine.diseaseSurgeryCross-Sectional StudiesItalyOral bisphopshonates; Osteonecrosis jaws; OsteoporosisHypertensionMultivariate AnalysisOsteoporosisBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusiness
researchProduct

Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus.

2011

Introduction: Pemphigus is an autoimmune blistering disease of the skin and mucous membranes characterized by the development of autoantibodies against the desmosomal proteins, desmoglein-1 and -3. Before the advent of corticosteroids, therapy was almost fatal. The introduction of high-dose corticosteroid therapy has reduced mortality rates to similar to 10%, but long-term use of steroids can lead to side effects, many of which are severe and associated with significant morbidity. Thus, the major goal of pemphigus therapy has been to reduce the patient's cumulative exposure to systemic corticosteroids. Over the last 2 decades, a range of corticosteroid-sparing immunosuppressive agents have …

medicine.medical_specialtyToxicologyMycophenolateMycophenolic acidPharmacokineticsAdrenal Cortex HormonesmedicineInitial treatmentimmunosuppressant inosine monophosphate dehydrogenase mycophenolate mofetil mycophenolic acid pemphigus pharmacokinetic treatmentHumansPharmacologyintegumentary systembusiness.industryMortality rateAutoantibodyGeneral MedicineMycophenolic Acidmedicine.diseaseDermatologyPemphigusImmunologybusinessImmunosuppressive AgentsPemphigusmedicine.drugBlistering diseaseExpert opinion on drug metabolismtoxicology
researchProduct

Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis.

2012

Ocular inflammatory disorders constitute a sight-threatening group of diseases that might be managed according to their severity. Their treatment guidelines experience constant changes with new agents that improve the results obtained with former drugs. Nowadays we can make use of a five step protocol in which topical, periocular and systemic corticosteroids remain as the main therapy for non-infectious uveitis. In addition, immunosuppresive drugs can be added in order to enhance the anti-inflammatory effects and to play the role of corticosteroid-sparing agents. These can be organized in four other steps: cyclosporine and methotrexate in a second one; azathioprine, mycophenolate and tacrol…

medicine.medical_specialtyTreatment protocolCyclophosphamideAdministration TopicalImmunologyAnti-Inflammatory AgentsAzathioprineUveitisInfectious uveitisAdrenal Cortex HormonesmedicineImmunology and AllergyAnimalsHumansIntensive care medicinePharmacologyChlorambucilbusiness.industryTumor Necrosis Factor-alphaGeneral Medicinemedicine.diseaseTacrolimusSurgeryInjections IntravenousPractice Guidelines as TopicMethotrexateImmunotherapybusinessUveitisAlgorithmsImmunosuppressive Agentsmedicine.drugInflammationallergy drug targets
researchProduct